“We are pleased to have Molecular Health on board in the near future as an experienced partner in precision medicine. With MH Guide, we can analyze and interpret molecular genetic data even faster and more comprehensively. This is an important addition to our service and product portfolio.”
Damla Bozkulak,
Head of Marketing and Business Development at Gen Era Diagnostics
Challenge
The rising demand for personalized treatment of cancer has forced oncologists and pathologists to grapple with a flood of data from genomic testing and a continually changing landscape of recommendations for therapies. Isolated interpretation of results from molecular tumor profiling can lead to unwanted disparities in patient care.
Solution
The annotation software MH Guide supports the interpretation of cancer gene variants based on up-to-date clinical research and internationally recognized recommendations and guidelines. With a wide distribution to 20 laboratories, Gen Era facilitates the harmonized translation of genomic data into actionable treatment decisions.
Patient benefit
The collaboration between Molecular Health and Gen Era Diagnostics is a true example of how a game-changing product combined with the market reach of a visionary enabler can accelerate much needed improvements in cancer care. The use of MH Guide across multiple laboratories not only standardizes genomic data interpretation, but also streamlines the evaluation of individual cases by oncologists and molecular tumor boards. Both aspects make the promise of precision medicine a reality for more patients.
With head offices in Bonn, Germany, GENOPATH GbR is an association of 16 pathology institutes. The group formed to supply all member laboratories with top-quality and cutting-edge molecular diagnostic services that complement existing histological and cytological methods, making the comprehensive care available to every cancer patient.
The OncoNet Rhein-Main is a network of clinics, molecular pathology laboratories, practices and medical centers that aims to provide effective and targeted care to all cancer patients in the Rhein-Main area. Working together, partners in the network support clinical studies to integrate innovative therapy approaches into daily clinical practice.
The Institute of Pathology at the Charité Berlin is a key player in the care of cancer patients of the country’s capital and surrounding area. Their broad spectrum of analytical methods covers histological, cytological, and molecular diagnostics to deliver the reliable and timely identification of therapeutic options.
© 2020 Molecular Health GmbH
© 2021 Molecular Health GmbH
© 2020 Molecular Health GmbH
